Landmark African trial finds early oral step-down non-inferior to prolonged IV antibiotics for severe childhood pneumonia

An open-label 2×5 factorial randomised controlled trial, run by the PediCAP Trial Group across 13 hospitals in five sub-Saharan African countries (1,101 children), tested stepping down to oral amoxicillin once a child improved clinically, with total antibiotic duration as short as four to five days Primary Study. This approach was non-inferior to WHO-standard intravenous-only care for 28-day readmission or death, with no signal of increased harm.

The trial population — children with severe community-acquired pneumonia in sub-Saharan Africa — does not transfer directly to an adult outpatient parenteral antimicrobial therapy caseload in a different health system, and this trial’s findings should not be read as directly applicable local guidance. It is included here as a landmark, high-powered randomised trial that reinforces a general antimicrobial stewardship principle rather than as evidence for a specific local pathway.

That general principle — early, protocol-driven step-down to oral therapy once a patient is clinically stable, rather than a fixed course of intravenous treatment — is the same mechanism underpinning IV-duration and outpatient antimicrobial therapy decisions in adult care internationally, independent of the specific population studied here.